Nadir SpO₂ (lowest SpO₂ during sleep) · Children with obstructive sleep apnoea (aged 15 years or younger)
1 finding from 1 review
Number of participants experiencing any serious adverse events · Children with obstructive sleep apnoea (aged 15 years or younger)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
AHI · Children with obstructive sleep apnoea (aged 15 years or younger)
1 finding from 1 review
Desaturation index (number of times per hour of sleep time that the blood's O₂ level drops by a certain proportion from baseline) · Children with obstructive sleep apnoea (aged 15 years or younger)
1 finding from 1 review
Respiratory arousal index (number of times per hour of sleep time that an increased respiratory effort without a decrease in oxygen saturation is recorded) · Children with obstructive sleep apnoea (aged 15 years or younger)
1 finding from 1 review
Nadir SpO₂ (lowest SpO₂ during sleep) · Children with obstructive sleep apnoea (aged 15 years or younger)
1 finding from 1 review
Short‐term abstinence from smoking (< 6 months) · Adult smokers
Interventions to increase adherence showed no clear difference in short‐term abstinence from smoking (< 6 months) compared with standard care (low certainty).
1 finding from 1 review
Abstinence · Adult smokers
Interventions to increase adherence showed no clear difference in long‐term abstinence from smoking (≥ 6 months) compared with standard care (low certainty).
1 finding from 1 review
Overall breast cancer incidence · women with above‐average risk of developing breast cancer
Tamoxifen probably leads to lower overall breast cancer incidence compared with placebo (moderate certainty).
1 finding from 1 review
Severe toxicity · women with above‐average risk of developing breast cancer
Tamoxifen probably leads to higher severe toxicity compared with placebo (moderate certainty).
1 finding from 1 review
Overall breast cancer incidence · women with above‐average risk of developing breast cancer
Aromatase inhibitors leads to lower overall breast cancer incidence compared with placebo (high certainty).
1 finding from 1 review
Severe toxicity · women with above‐average risk of developing breast cancer
Aromatase inhibitors leads to higher severe toxicity compared with placebo (high certainty).
1 finding from 1 review
Overall breast cancer incidence · women with above‐average risk of developing breast cancer
Aromatase inhibitors may leads to lower overall breast cancer incidence compared with tamoxifen (indirect comparison)a (low certainty).
1 finding from 1 review
Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether CHOLINERGIC DRUGS changes tardive dyskinesia: No clinically important improvement compared with PLACEBO (very low certainty).
1 finding from 1 review
Tardive dyskinesia: Deterioration of symptoms · patients with antipsychotic‐induced tardive dyskinesia
CHOLINERGIC DRUGS showed no clear difference in tardive dyskinesia: Deterioration compared with PLACEBO (low certainty).
1 finding from 1 review
General mental state: Deterioration · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether CHOLINERGIC DRUGS changes mental state: Deterioration compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse effects: Any adverse events · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether CHOLINERGIC DRUGS changes adverse effects: Any adverse events compared with PLACEBO (very low certainty).
1 finding from 1 review
Secondary outcome: acceptability of treatment · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether CHOLINERGIC DRUGS changes acceptability of treatment: Leaving the study early compared with PLACEBO (very low certainty).
1 finding from 1 review
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Live birth rate per woman · for controlled ovarian stimulation
Clomiphene citrate or letrozole with or without gonadotropins (with… showed no clear difference in live birth per woman compared with gonadotropins (with GnRH agonists or midcycle antagonist) (low certainty).
1 finding from 1 review